MedTrace Logo

Formulation and Food Effect Study of AZD1386 in Healthy Volunteers

NCT00714337 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2010-12-10

No results posted yet for this study

Summary

To investigate the pharmacokinetics of two oral solid formulations of AZD1386 in relation to the AZD1386 oral solution.

Conditions

  • Pharmacokinetics

Interventions

DRUG

AZD1386

One single oral dose of 90mg (36mL of AZD1386 2.5mg/mL oral solution).

DRUG

AZD1386

One single oral dose of 90mg (3 x 30mg AZD1386 capsules)

DRUG

AZD1386

One single oral dose of 90mg (6 x 15mg AZD1386 tablets)

Sponsors & Collaborators

Principal Investigators

  • Klaus Francke, MD · PAREXEL Clinical Pharmacology Research Unit

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
20 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-06-30
Primary Completion
2008-08-31
Completion
2008-08-31

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00714337 on ClinicalTrials.gov